RBC keeps USD 56.00 target for Alkermes stock

Published on 10/15/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alkermes has an estimated earnings date of October 28, 2026. Alkermes stock costs EUR 35.30 on October 15, 2026, up 1.50 percent on Nasdaq.

Analyst target and earnings date

RBC Capital maintained an Outperform rating and a USD 56.00 target on September 22, 2026.
Alkermes has an estimated next earnings date of October 28, 2026.
Alkermes stock costs EUR 35.30 at Lang & Schwarz on October 15, 2026 at 9:01 p.m. CEST, up 1.50 percent on Nasdaq.
Alkermes gained 39.67 percent year to date through October 14, 2026.

ALKS, IE00B56GVS15, Illustration mit AI erstellt.

RBC Capital maintained its Outperform rating and USD 56.00 price target for Alkermes on September 22, 2026, putting the target 41.20 percent above the USD 39.66 Nasdaq price. The assessment gives the stock a clear valuation marker while the market waits for the next scheduled results update, according to Yahoo Finance. At Lang & Schwarz, Alkermes was priced at EUR 35.30 on October 15, 2026 at 9:01 p.m. CEST, while Nasdaq data showed a 1.50 percent gain on the day.

October 28 sets the next date

Yahoo Finance lists October 28, 2026 as Alkermes' estimated next earnings date. The date matters because the company reported USD 496.01 million in revenue for the second quarter of 2026, according to Markets Insider. That figure compares with USD 390.66 million in the year-earlier quarter, an increase of 26.96 percent.

39.67 percent year to date

Alkermes gained 39.67 percent year to date through October 14, 2026, compared with a 12.76 percent gain for the S&P 500 over the same period, according to Yahoo Finance. The stock traded between USD 27.00 and USD 55.67 over the preceding 52 weeks. At USD 39.66, it stood 28.84 percent below that high. The latest intraday Nasdaq quote carried 1,278,979 shares of volume against an average of 1,854,129 shares.

Valuation and peer comparison

Alkermes had a market capitalization of USD 6.7 billion and a trailing P/E ratio of 103.38 on October 15, 2026. The valuation sits above Bristol-Myers Squibb's P/E of 13.40 and United Therapeutics' P/E of 19.63, although the companies differ in size and product mix.

Comparison with peers

Alkermes (Nasdaq, USD): plus 1.50 percent, P/E 103.38, market capitalization USD 6.7 billion. Bristol-Myers Squibb (NYSE, USD): plus 2.67 percent, P/E 13.40, market capitalization USD 124.3 billion. United Therapeutics (Nasdaq, USD): plus 1.40 percent, P/E 19.63, market capitalization USD 23.5 billion.

The euro quote after hours

For investors in Germany, the key distinction is between the euro quotation and the home-market figures. The Lang & Schwarz price was EUR 35.30 in after-hours trading, while the Nasdaq quotation stood at USD 39.66 during the October 15 session. The next dated item is the estimated October 28 results release, and the current analyst marker remains RBC Capital's USD 56.00 target.

The further course of trading is shown by the continuously updated real-time quote of Alkermes stock.